Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Breast cancer, metastatic 2

274O - Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study


21 Sep 2020


Proffered Paper - Breast cancer, metastatic 2


Tumour Site

Breast Cancer


Michael Friedlander


Annals of Oncology (2020) 31 (suppl_4): S348-S395. 10.1016/annonc/annonc268


M. Friedlander1, V. Dieras2, B. Arun3, H.S. Han4, H. Wildiers5, J.P. Ayoub6, S. Puhalla7, S. Hudgens8, L. Floden9, N. Khandelwal10, K. Benjamin11, R. Kamalakar12, D. Maag13

Author affiliations

  • 1 Medical Oncology, The Prince of Wales Hospital, Sydney/AU
  • 2 Department Of Medical Oncology, Centre Eugène Marquis Rennes, Institut Curie, 35042 - Paris/FR
  • 3 Department Of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 4 Department Of Breast Oncology, Moffitt Cancer Center and Research Institute, Tampa/US
  • 5 Department Of Oncology, UZ Leuven, Leuven/BE
  • 6 Department Of Medicine, Centre hospitalier de l'Université de Montréal, Montréal/CA
  • 7 Division Of Hematology And Oncology, University of Pittsburgh Medical Center, Pittsburgh/US
  • 8 Regulatory & Access, Clinical Outcomes Solutions, Tucson/US
  • 9 Biostatistics, Clinical Outcomes Solutions, Tucson/US
  • 10 Global Health Economics And Outcomes Research, AbbVie Inc, 60064 - North Chicago/US
  • 11 Patient Reported Outcomes, AbbVie Inc, North Chicago/US
  • 12 Analytics, AbbVie Inc, North Chicago/US
  • 13 Global Health Economics And Outcomes Research, AbbVie Inc, North Chicago/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 274O


Veliparib, a poly (ADP-ribose) polymerase 1/2 inhibitor, was evaluated in the phase III BROCADE 3 study (NCT02163694) for efficacy and safety in combination with paclitaxel/carboplatin (VPC) in pts with HER2-negative metastatic or locally advanced unresectable gBRCA-associated breast cancer, in which VPC significantly prolonged progression-free survival (hazard ratio=0.71 [95% CI 0.57, 0.88], P=.002) compared with placebo plus paclitaxel/carboplatin (PPC) (Dieras VC et al. Ann Oncol. 2019:30[suppl 5]:LBA9). In this analysis we investigated the impact of veliparib on HRQoL.


This double-blind study examined the effect of veliparib (120 mg oral twice daily for 7 days out of each 21-day cycle) added to paclitaxel/carboplatin vs. PPC. HRQoL measures were EORTC-QLQ -C30 and breast cancer (BR23), EQ-5D-5L, and Brief Pain Inventory-Short Form (BPI-SF). Responses were obtained on Day 2 Cycle 1, Day 1 Cycle 2, and every other cycle thereafter starting from Cycle 4 plus final and follow-up visit. Data were analyzed only through Day 1 Cycle 30 due to attrition. For each HRQoL domain, mean change in baseline scores, % responders (improved, stable, declined), and median time to symptom worsening were analyzed across study arms.


504 pts (VPC 334, PPC 170) were included in the analysis. Improvement from baseline in function, disease and treatment symptom burden, and health state was observed for both study arms, with greater benefits for VPC vs. PPC for pain, pain interference, and breast symptoms. Greater proportion of PPC vs. VPC pts declined in global health status, pain, arm symptoms, breast symptoms and pain interference, but here differences were not significant. Median time (months) to symptom worsening was significantly longer (P<0.05) for VPC vs. PPC pts for role functioning (8.2 vs. 6.5), physical functioning (8.8 vs. 7.1), constipation (7.7 vs. 6.2), and future perspectives (10.2 vs. 9.0).


Overall, addition of veliparib to paclitaxel/carboplatin has no detrimental effect on quality of life in pts with gBRCA mutation-associated advanced breast cancer and may be beneficial in some areas of functioning and symptom experience.

Clinical trial identification


Editorial acknowledgement

Medical writing services, provided by Alan Saltzman of JK Associates, Inc., were funded by AbbVie.

Legal entity responsible for the study

AbbVie Inc.




V. Dieras: Advisory/Consultancy: Roche/Genentech; Advisory/Consultancy: Novartis; Advisory/Consultancy: Lilly; Advisory/Consultancy: Pfizer; Advisory/Consultancy: AbbVie; Advisory/Consultancy: MSD; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: AstraZeneca. B. Arun: Leadership role, Research grant/Funding (institution), Steering committee (non-paid): AbbVie; Research grant/Funding (institution): PharmaMar; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Invitae. H.S. Han: Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Prescient; Research grant/Funding (institution): Horizon; Research grant/Funding (institution): Karyopharm; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): TapImmune; Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (institution): Department of Defense; Speaker Bureau/Expert testimony: Lilly. H. Wildiers: Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Lilly; Honoraria (institution), Advisory/Consultancy: Novartis; Honoraria (institution), Advisory/Consultancy: AbbVie; Honoraria (institution), Advisory/Consultancy: Vifor Pharma; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (institution), Advisory/Consultancy: Celldex Therapeutics; Honoraria (institution), Advisory/Consultancy: Janssen-Cilag; Honoraria (institution), Advisory/Consultancy: TRM Oncology; Honoraria (institution), Advisory/Consultancy: PUMA Biotechnology; Honoraria (institution), Advisory/Consultancy: Amgen; Honoraria (institution), Advisory/Consultancy: Orion Corporation. M. Friedlander: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Leadership role, Steering committee (remunerated): MSD; Advisory/Consultancy, Leadership role, Steering committee (non-remunerated): AbbVie; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy: Takeda; Honoraria (self), Advisory/Consultancy: Novartis; Research grant/Funding (institution): BeiGene. J.P. Ayoub: Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Boston Biomedical; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Eisai; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy: Puma; Advisory/Consultancy: Roche. S. Puhalla: Advisory/Consultancy, Research grant/Funding (institution): AbbVie; Advisory/Consultancy: MedImmune; Advisory/Consultancy: Celldex; Advisory/Consultancy: Puma; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Eisai; Advisory/Consultancy: NanoString; Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): Covance-Bayer; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Medivation. S. Hudgens: Full/Part-time employment: Clinical Outcomes Solutions. L. Floden: Full/Part-time employment: Clinical Outcomes Solutions. N. Khandelwal: Shareholder/Stockholder/Stock options, Full/Part-time employment: AbbVie. K. Benjamin: Shareholder/Stockholder/Stock options, Full/Part-time employment: AbbVie. R. Kamalakar: Shareholder/Stockholder/Stock options, Full/Part-time employment: AbbVie. D. Maag: Shareholder/Stockholder/Stock options, Full/Part-time employment: AbbVie.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.